- Home
- ACRS vs ALGS Comparison
ACRS vs ALGS Comparison
Compare ACRS & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- ALGS
- Stock Information
- Founded
- ACRS 2012
- ALGS 2018
- Country
- ACRS United States
- ALGS United States
- Employees
- ACRS N/A
- ALGS N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- ACRS Health Care
- ALGS Health Care
- Exchange
- ACRS Nasdaq
- ALGS Nasdaq
- Market Cap
- ACRS 132.0M
- ALGS 118.8M
- IPO Year
- ACRS 2015
- ALGS 2020
- Fundamental
- Price
- ACRS $2.24
- ALGS $18.63
- Analyst Decision
- ACRS Strong Buy
- ALGS Strong Buy
- Analyst Count
- ACRS 5
- ALGS 1
- Target Price
- ACRS $11.00
- ALGS $75.00
- AVG Volume (30 Days)
- ACRS 656.6K
- ALGS 268.0K
- Earning Date
- ACRS 03-04-2025
- ALGS 03-11-2025
- Dividend Yield
- ACRS N/A
- ALGS N/A
- EPS Growth
- ACRS N/A
- ALGS N/A
- EPS
- ACRS N/A
- ALGS N/A
- Revenue
- ACRS $27,079,000.00
- ALGS $5,997,000.00
- Revenue This Year
- ACRS N/A
- ALGS N/A
- Revenue Next Year
- ACRS N/A
- ALGS N/A
- P/E Ratio
- ACRS N/A
- ALGS N/A
- Revenue Growth
- ACRS 26.35
- ALGS N/A
- 52 Week Low
- ACRS $0.95
- ALGS $6.76
- 52 Week High
- ACRS $5.17
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- ACRS 39.59
- ALGS 33.33
- Support Level
- ACRS $2.11
- ALGS $20.12
- Resistance Level
- ACRS $2.42
- ALGS $24.33
- Average True Range (ATR)
- ACRS 0.15
- ALGS 2.67
- MACD
- ACRS 0.00
- ALGS -0.38
- Stochastic Oscillator
- ACRS 26.53
- ALGS 4.38
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.